Lung Cancer Dispatch
4.7K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

New Tool Predicts Financial Pain for Cancer Patients

New Tool Predicts Financial Pain for Cancer Patients | Lung Cancer Dispatch | Scoop.it

"In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to tolerate, financial stress. The researchers refer to the expense, anxiety, and loss of confidence confronting cancer patients who face large, unpredictable costs, often compounded by decreased ability to work, as “financial toxicity,” and they have named their patient-reported outcome measure COST (COmprehensive Score for financial Toxicity)."

Cancer Commons's insight:

The ASCO Post  |  Jun 20, 2014

more...
Cancer Commons's curator insight, June 20, 2014 1:55 PM

The ASCO Post  |  Jun 20, 2014

Cancer Commons's curator insight, June 20, 2014 1:56 PM

The ASCO Post  |  Jun 20, 2014

Scooped by Cancer Commons
Scoop.it!

Lung Cancer Screening Would Cost Medicare Billions

Lung Cancer Screening Would Cost Medicare Billions | Lung Cancer Dispatch | Scoop.it

"Implementation of a national lung cancer screening program using low-dose computed tomography (LDCT) will identify almost 55,000 additional lung cancer cases over 5 years, but will add more than $9 billion to Medicare expenditures, according to results of a new study.


"Joshua A. Roth, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, discussed the economic analysis during a press conference in advance of the American Society of Clinical Oncology (ASCO) Annual Meeting, where results will be formally presented at the end of the month. He noted that following the positive results of the National Lung Screening Trial, the US Preventive Services Task Force recently recommended LDCT screening in healthy persons between the ages of 55 and 80 with at least 30 pack-years of smoking history. Medicare, meanwhile, is expected to release a draft decision on screening coverage in November of this year. 'That decision will likely heavily weight the Task Force’s recommendation,' Roth said."

Cancer Commons's insight:

Cancer Network  |  May 15, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Living With Cancer: The Cost of Trials

Living With Cancer: The Cost of Trials | Lung Cancer Dispatch | Scoop.it

"A recent CT scan made me realize that the clinical trial extending my life effectively excludes all but the most privileged cancer patients.

"I used to weasel out of scans. Chalk it up to trepidation about radiation and possible kidney damage, along with paranoid suspicions that such scans don’t yield definitive pictures. My oncologist and I had agreed to fudge on frequent testing. But the clinical trial did not."


Editor's Note: Learn more about clinical trials here.

Cancer Commons's insight:

The New York Times  |  Mar 20, 2014

more...
Cancer Commons's curator insight, March 21, 2014 3:51 PM

The New York Times  |  Mar 20, 2014

Cancer Commons's curator insight, March 21, 2014 3:51 PM

The New York Times  |  Mar 20, 2014

Scooped by Cancer Commons
Scoop.it!

EML4-ALK Fusion Testing, Targeted Crizotinib Treatment Not Cost-Effective in NSCLC

EML4-ALK Fusion Testing, Targeted Crizotinib Treatment Not Cost-Effective in NSCLC | Lung Cancer Dispatch | Scoop.it

"EML4-ALK fusion testing to identify patients with advanced non–small cell lung cancer eligible for first-line, targeted treatment with crizotinib may not be cost-effective, according to study results.

"Researchers in Ontario used a Markov model to compare the cost-effectiveness of two treatment approaches for patients with stage IV nonsquamous NSCLC. One approach consisted of molecular screening and targeted treatment with crizotinib (Xalkori, Pfizer). The other approach consisted of standard care, which included platinum doublet (cisplatin and gemcitabine) as first-line therapy, second-line pemetrexed (Alimta, Eli Lilly) and third-line erlotinib (Tarceva; Genentech, Astellas Pharma)."


Editor's Note: Molecular testing can be used to identify genetic mutations in a patient's tumor that may point to the use of a certain treatment, personalized for him or her. This study explores the costs associated with these treatments. Of course, every patient's treatment decisions will be made for his or her own personal reasons. You can talk to your doctor to find out if molecular testing and targeted therapies are good choices for you.

Cancer Commons's insight:

Healio  |  Mar 17, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

What Cancer Costs You Later: $4,000 a Year

What Cancer Costs You Later: $4,000 a Year | Lung Cancer Dispatch | Scoop.it

"Having cancer is bad enough. And the lifetime consequences have been well-documented — a higher risk of other cancers, heart disease and general weakness from the treatment.


"Now a new federal study shows there’s a financial burden too — on average, $4,000 a year for men and $3,000 for women over and above what people who haven’t had cancer spend.


"And that’s just direct medical costs. Cancer survivors also have thousands in lost productivity, from having to cut work hours or even quit their jobs, the report finds."

Cancer Commons's insight:

NBC News  |  Jun 12, 2014

more...
Cancer Commons's curator insight, June 16, 2014 2:20 PM

NBC News  |  Jun 12, 2014

Cancer Commons's curator insight, June 16, 2014 2:20 PM

NBC News  |  Jun 12, 2014

Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

IMS Study Shows Cancer Treatment Costs Driven Up by 340B Drug Pricing Program

IMS Study Shows Cancer Treatment Costs Driven Up by 340B Drug Pricing Program | Lung Cancer Dispatch | Scoop.it

"The IMS Institute for Healthcare Informatics issued a detailed report titled, 'Innovations in Cancer Care and Implications for Health Systems,' and the Alliance for Integrity and Reform of 340B said the report shows that the drug discount program is a driver in the rise in treatment costs for patients with cancer."

Cancer Commons's insight:

Healio  |  May 13, 2014

more...
Cancer Commons's curator insight, May 13, 2014 3:13 PM

Healio  |  May 13, 2014

Cancer Commons's curator insight, May 13, 2014 3:13 PM

Healio  |  May 13, 2014

Scooped by Cancer Commons
Scoop.it!

ASCO Sets Up Framework to Improve Cancer Care

ASCO Sets Up Framework to Improve Cancer Care | Lung Cancer Dispatch | Scoop.it

"A new report, published by the American Society of Clinical Oncology (ASCO) in the Journal of Oncology Practice and presented in part via a live Webcast in Washington, DC, outlined the current and future challenges of cancer care in the United States. An increasing cost of care and demand for quality care, growing cancer patient and cancer survivor populations, and a decreasing oncology workforce are all contributing to a challenging environment for cancer care."

Cancer Commons's insight:

Cancer Network  |  Mar 19, 2014

more...
Cancer Commons's curator insight, March 20, 2014 1:55 PM

Cancer Network  |  Mar 19, 2014

Cancer Commons's curator insight, March 20, 2014 1:56 PM

Cancer Network  |  Mar 19, 2014